Cargando…

Safety and efficacy of amphotericin-B deoxycholate inhalation in critically ill patients with respiratory Candida spp. colonization: a retrospective analysis

BACKGROUND: Candida spp. are frequently cultured from the respiratory tract in critically ill patients. Most intensivists start amphotericin-B deoxycholate (ABDC) inhalation therapy to eradicate Candida spp. from the respiratory tract. However, the safety and efficacy of this treatment are not well...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Geest, Patrick J, Dieters, Erik I, Rijnders, Bart, Groeneveld, Johan AB
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213474/
https://www.ncbi.nlm.nih.gov/pubmed/25348856
http://dx.doi.org/10.1186/s12879-014-0575-3
_version_ 1782341822230560768
author van der Geest, Patrick J
Dieters, Erik I
Rijnders, Bart
Groeneveld, Johan AB
author_facet van der Geest, Patrick J
Dieters, Erik I
Rijnders, Bart
Groeneveld, Johan AB
author_sort van der Geest, Patrick J
collection PubMed
description BACKGROUND: Candida spp. are frequently cultured from the respiratory tract in critically ill patients. Most intensivists start amphotericin-B deoxycholate (ABDC) inhalation therapy to eradicate Candida spp. from the respiratory tract. However, the safety and efficacy of this treatment are not well established. The purpose of this study was to assess the safety and efficacy of ABDC inhalation for the treatment of respiratory Candida spp. colonization in critically ill patients. METHODS: All non-neutropenic patients admitted into the intensive care unit (ICU) of a university hospital from December 2010–2011, who had positive Candida spp. cultures of the respiratory tract for more than 1 day and required mechanical ventilation >48 h were retrospectively included. The decision to start ABDC inhalation had been made by attending intensivists on clinical grounds in the context of selective decontamination of the digestive tract. Infection characteristics and patient courses were assessed. RESULTS: Hundred and thirteen consecutive patients were studied. Fifty-one of them received ABDC inhalation and their characteristics at baseline and day 1 of respiratory colonization did not differ from those of colonized patients not receiving treatment (n = 62). The ABDC-treated group had a similar Candida spp. load but did not decolonize more rapidly as compared to untreated patients. The clinical pulmonary infection and lung injury scores did not decrease as in the untreated group. In a Cox proportional hazard model, the duration of mechanical ventilation was increased (P < 0.003) by ABDC treatment independently of other potential determinants and Candida spp. colonization. No differences in ventilator-associated pneumonia or in overall mortality (up to day 90) were observed. CONCLUSION: Treatment of respiratory Candida spp. colonization in non-neutropenic critically ill patients by inhaled ABDC may not affect respiratory colonization but may increase duration of mechanical ventilation, because of direct toxicity of the drug on the lung. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0575-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4213474
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42134742014-10-31 Safety and efficacy of amphotericin-B deoxycholate inhalation in critically ill patients with respiratory Candida spp. colonization: a retrospective analysis van der Geest, Patrick J Dieters, Erik I Rijnders, Bart Groeneveld, Johan AB BMC Infect Dis Research Article BACKGROUND: Candida spp. are frequently cultured from the respiratory tract in critically ill patients. Most intensivists start amphotericin-B deoxycholate (ABDC) inhalation therapy to eradicate Candida spp. from the respiratory tract. However, the safety and efficacy of this treatment are not well established. The purpose of this study was to assess the safety and efficacy of ABDC inhalation for the treatment of respiratory Candida spp. colonization in critically ill patients. METHODS: All non-neutropenic patients admitted into the intensive care unit (ICU) of a university hospital from December 2010–2011, who had positive Candida spp. cultures of the respiratory tract for more than 1 day and required mechanical ventilation >48 h were retrospectively included. The decision to start ABDC inhalation had been made by attending intensivists on clinical grounds in the context of selective decontamination of the digestive tract. Infection characteristics and patient courses were assessed. RESULTS: Hundred and thirteen consecutive patients were studied. Fifty-one of them received ABDC inhalation and their characteristics at baseline and day 1 of respiratory colonization did not differ from those of colonized patients not receiving treatment (n = 62). The ABDC-treated group had a similar Candida spp. load but did not decolonize more rapidly as compared to untreated patients. The clinical pulmonary infection and lung injury scores did not decrease as in the untreated group. In a Cox proportional hazard model, the duration of mechanical ventilation was increased (P < 0.003) by ABDC treatment independently of other potential determinants and Candida spp. colonization. No differences in ventilator-associated pneumonia or in overall mortality (up to day 90) were observed. CONCLUSION: Treatment of respiratory Candida spp. colonization in non-neutropenic critically ill patients by inhaled ABDC may not affect respiratory colonization but may increase duration of mechanical ventilation, because of direct toxicity of the drug on the lung. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0575-3) contains supplementary material, which is available to authorized users. BioMed Central 2014-10-28 /pmc/articles/PMC4213474/ /pubmed/25348856 http://dx.doi.org/10.1186/s12879-014-0575-3 Text en © van der Geest et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
van der Geest, Patrick J
Dieters, Erik I
Rijnders, Bart
Groeneveld, Johan AB
Safety and efficacy of amphotericin-B deoxycholate inhalation in critically ill patients with respiratory Candida spp. colonization: a retrospective analysis
title Safety and efficacy of amphotericin-B deoxycholate inhalation in critically ill patients with respiratory Candida spp. colonization: a retrospective analysis
title_full Safety and efficacy of amphotericin-B deoxycholate inhalation in critically ill patients with respiratory Candida spp. colonization: a retrospective analysis
title_fullStr Safety and efficacy of amphotericin-B deoxycholate inhalation in critically ill patients with respiratory Candida spp. colonization: a retrospective analysis
title_full_unstemmed Safety and efficacy of amphotericin-B deoxycholate inhalation in critically ill patients with respiratory Candida spp. colonization: a retrospective analysis
title_short Safety and efficacy of amphotericin-B deoxycholate inhalation in critically ill patients with respiratory Candida spp. colonization: a retrospective analysis
title_sort safety and efficacy of amphotericin-b deoxycholate inhalation in critically ill patients with respiratory candida spp. colonization: a retrospective analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213474/
https://www.ncbi.nlm.nih.gov/pubmed/25348856
http://dx.doi.org/10.1186/s12879-014-0575-3
work_keys_str_mv AT vandergeestpatrickj safetyandefficacyofamphotericinbdeoxycholateinhalationincriticallyillpatientswithrespiratorycandidasppcolonizationaretrospectiveanalysis
AT dieterseriki safetyandefficacyofamphotericinbdeoxycholateinhalationincriticallyillpatientswithrespiratorycandidasppcolonizationaretrospectiveanalysis
AT rijndersbart safetyandefficacyofamphotericinbdeoxycholateinhalationincriticallyillpatientswithrespiratorycandidasppcolonizationaretrospectiveanalysis
AT groeneveldjohanab safetyandefficacyofamphotericinbdeoxycholateinhalationincriticallyillpatientswithrespiratorycandidasppcolonizationaretrospectiveanalysis